Nicholas Hornstein, Assistant Professor at Northwell Health, shared a post on X:
“Anyone else head swimming with the tsunami of RAS therapies that are coming out? Mine has been. I put together some of the most recent data; hopefully a little helpful for some people.
KRAS inhibitor data from AACR2026 and prior – compiled into a comparison table across G12C, G12D, and Pan-RAS programs. G12C OFF-state, RAS(ON) selective, G12D, and Pan-RAS. 18 G12C entries, G12D and Pan-RAS programs included. Not exhaustive, some very good therapies aren’t on the list like Avutometinib.
Full table images below.”
Other articles featuring Nicholas Hornstein on OncoDaily.
